Aloxistatin [E-64d]
Overview | |
Catalog # | bs-75618c-1mg |
Product Name | Aloxistatin [E-64d] |
Specifications | |
Storage Buffer | Powder |
Storage Condition | Stable for 2 years after receipt when stored at -20°C. |
Target | |
Product Information | CAS Number: 88321-09-9 Molecular formula: C17H30N2O5 Molecular weight: 342.4 Purity: >95% (HPLC) Appearance: White to off-white powder. Solubility: Soluble in DMSO (20mg/ml), DMF (20mg/ml) or ethanol (5mg/ml). InChiKey: SRVFFFJZQVENJC-IHRRRGAJSA-N SMILES: O=C(OCC)[C@H]1O[C@@H]1C(N[C@H](C(NCCC(C)C)=O)CC(C)C)=O |
Description | Aloxistatin [E-64d] is a cell permeable irreversible inhibitor of lysosomal and cytosolic cysteine proteases cathepsin B an L, calpain 1/2, papain and has diverse biological activities. It is an ethyl ester form of E-64c that inhibits calpain and the cysteine proteases cathepsins F, K, B, H, and L. Aloxistatin has anticancer properties by inducing cell cycle arret at the G2/M phase in A431 human epidermoid carcinoma cells and as a lysosomal inhibitor in human acute promyelocytic leukemia NB4 cells and Huh-7 cells. It inhibits degradation of autophagic cargo inside autolysosomes. It also shows neuroprotective and anti-malarial properties. Since cysteine protease cathepsin L is required for SARS-CoV-2 viral entry, aloxistatin treatment reduces cellular entry of SARS-CoV-2 pseudovirions and COVID-19. It inhibits severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 surface glycoprotein incorporation into pseudotyped vesicular stomatitis virus (VSV) particles in Vero cells. Is has been applied in vitro in combination with the TMPRSS2 inhibitor camostat mesylate (Prod. No. bs-75597C). |